- Patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) experienced high, durable responses at half the approved daily dose of dasatinib.
Why this matters
- Reduced dasatinib dose may support maintained efficacy by reducing interruptions resulting from adverse events.
- Study to provide updated long-term outcomes in 81 patients treated with low-dose (50 mg/day) frontline dasatinib for Ph+ CML-CP.
- Funding: MD Anderson Cancer Center Leukemia Specialized Program of Research Excellence; Charif Souki Cancer Research Fund; NIH.
- BCR-ABL1 transcripts at 3 months:
- ≤10%: 96%.
- ≤1%: 77%.
- Cumulative complete cytogenetic response (CCyR):
- 77% at 6 months; 95% at 12 months; 98% estimated at 18 months.
- Cumulative major molecular responses (MMR):
- 4.0-log reduction: 22% at 6 months; 55% at 12; 68% estimated at 18 months.
- 4.5-log reduction: 15% at 6 months; 49% at 12; 59% estimated at 18 months.
- At the time of analysis, 77 patients remained in the trial, 5 patients experienced treatment failure.
- 100% 2-year event-free survival and OS.
- Treatment was generally well tolerated.
- 66% of patients had low-risk disease per Sokal score.